恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

休市中 05-29 16:08:26

60.200

+2.000

+3.44%

最高60.500	最低57.250	成交量636.97万
今开58.950	昨收58.200	日振幅5.58%
总市值3,995亿	流通市值155.32亿	总股本66.37亿
成交额3.78亿	换手率2.47%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":60.2,"timestamp":1780042106002,"preClose":58.2,"halted":0,"volume":6369651,"delay":0,"changeRate":0.034364261168384876,"floatShares":258000000,"shares":6637000000,"eps":1.36724492754759,"marketStatus":"休市中","change":2,"latestTime":"05-29 16:08:26","open":58.95,"high":60.5,"low":57.25,"amount":377672950,"amplitude":0.055842,"askPrice":60.2,"askSize":4600,"bidPrice":60.1,"bidSize":400,"shortable":3,"etf":0,"ttmEps":1.4144241470051178,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":7,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":58.2,"dividendRate":0.003833,"openAndCloseTimeList":[[1780018200000,1780027200000],[1780030800000,1780041600000]],"volumeRatio":1.5673522760745566,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":50.19,"timestamp":1780038000000,"preClose":48,"halted":0,"volume":130040400,"delay":0,"premium":"+3.52"}},"requestUrl":"/m/hq/s/01276/tweets","defaultTab":"tweets","newsList":[{"id":"2639676739","title":"恒瑞医药：公司将继续大力推进“科技创新”和“国际化”两大发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676739","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676739?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:59","pubTimestamp":1780066740,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，公司将继续大力推进“科技创新”和“国际化”两大发展战略，稳步推进研发创新和制剂产品的国际化。同时，也将着力于产品结构的优化提升，通过产品创新升级和多元化产品管线的拓展推动公司的持续发展，促进公司业绩可持续增长，以更好的发展回馈股东。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754793698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","BK0188","LU1997245177.USD","BK0239","LU2543165471.USD","BK0183","LU1064131003.USD","BK0060","LU1969619763.USD","LU1064130708.USD","LU2495084118.USD","600276","LU2488822045.USD","LU2148510915.USD","LU0405327148.USD","LU1781817850.SGD","LU1023057109.AUD","LU1997245094.SGD","LU2097828474.EUR","LU2097828557.USD","LU0405327494.USD","LU1580142542.USD","LU2289578879.USD","LU2580892862.HKD","LU2097828714.EUR","LU1820825898.SGD","LU1655091616.SGD","LU2580892789.USD","LU1997244956.HKD","LU1328615791.USD","BK0012","LU1255011170.USD","LU0359201885.HKD","01276","LU1146622755.USD","LU0359201612.USD","LU2097828631.EUR","BK0028","LU0359202008.SGD","LU2328871848.SGD","LU2097828805.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676731","title":"恒瑞医药：公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676731","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676731?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:58","pubTimestamp":1780066680,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，为保障2025年年度权益分派方案实施，公司本轮回购工作自权益分派实施筹备工作启动之日至权益分派实施完毕期间暂停。公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754790498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU1023057109.AUD","LU2148510915.USD","LU0405327494.USD","01276","LU2495084118.USD","600276","BK0012","LU1997245094.SGD","BK0196","LU0359201612.USD","LU0359201885.HKD","BK0188","LU1781817850.SGD","LU1255011170.USD","LU1146622755.USD","BK0183","LU2580892862.HKD","LU2580892789.USD","LU0359202008.SGD","LU1820825898.SGD","LU1064130708.USD","LU2328871848.SGD","LU1997245177.USD","LU2488822045.USD","BK0060","LU1064131003.USD","LU1328615791.USD","LU1969619763.USD","LU2097828474.EUR","LU2097828714.EUR","LU0405327148.USD","LU2097828631.EUR","LU2097828805.USD","LU2097828557.USD","LU1655091616.SGD","BK1191","LU1580142542.USD","LU2543165471.USD","LU1997244956.HKD","LU2289578879.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676986","title":"恒瑞医药：公司目前已在中国获批上市25款1类创新药、5款2类新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676986","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676986?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:48","pubTimestamp":1780066080,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持科技创新战略，目前已在中国获批上市25款1类创新药、5款2类新药，另有100多个自主创新产品正在临床开发，400余项临床试验在国内外开展。经营业绩方面，创新成果转化高效赋能，创新药销售引领业绩增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754780227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0405327494.USD","LU2148510915.USD","BK1161","LU1997245094.SGD","LU2289578879.USD","LU0359201612.USD","BK1574","BK0012","LU0359202008.SGD","LU1328615791.USD","LU1064131003.USD","600276","BK0028","BK1191","IPOS","LU1655091616.SGD","LU2097828474.EUR","LU1255011170.USD","LU2328871848.SGD","LU2097828714.EUR","LU2488822045.USD","LU2580892789.USD","BK0196","LU1781817850.SGD","BK0188","LU2097828557.USD","BK0183","LU0405327148.USD","LU1997245177.USD","LU1064130708.USD","BK0060","LU2495084118.USD","06978","LU1580142542.USD","BK0239","01276","LU2097828631.EUR","LU2097828805.USD","LU0359201885.HKD","LU1969619763.USD","LU1023057109.AUD","LU1997244956.HKD","LU1146622755.USD","LU2543165471.USD","LU1820825898.SGD","LU2580892862.HKD","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639035620","title":"恒瑞医药：2025年全年公司实现营业收入316.29亿元，同比增长13.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639035620","media":"证券日报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639035620?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:09","pubTimestamp":1780056540,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，二级市场波动受多重因素影响，公司经营业绩稳步提升，整体发展态势持续向好。2025年全年，公司实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%。2026年第一季度，公司实现营业收入81.41亿元，同比增长12.98%；归属于上市公司股东的净利润22.82亿元，同比增长21.78%。公司始终高度重视全体股东利益，致力于发展好主营业务，促进公司业绩可持续增长，以更好的发展回馈股东。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-29/doc-inhzqptf9386509.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-29/doc-inhzqptf9386509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639640961","title":"智通AH统计|5月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2639640961","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639640961?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:15","pubTimestamp":1780042506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月29日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为650.00%、386.43%、319.67%；宁德时代、兆易创新、药明康德分列AH溢价率末三位，溢价率分别为-31.78%、-23.44%、-6.60%。其中大唐发电、东北电气、晨鸣纸业的偏离值位居前三，分别为92.26%、74.26%、43.10%；另外，胜宏科技、福莱特玻璃、中国人寿的偏离值位居后三，分别为-13.11%、-12.48%、-9.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06865","00553","03145","02218","01812","03678","00883","06031","HPAD.SI","00956","03347","LU0348814723.USD","01033","02359","02238","03750","PAImain","03968","02628","LU2476274720.SGD","80883","LU0890818403.SGD","EWH","01898","00916","01276","01057","02338","02601","00719","03268","03986","LU0254981946.USD","601318","159982","BK1521","00568","00991","02476","03143","03296","PNGAY","01349","82318","03328","02318","00042","00588","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118674931","title":"异动解读｜恒瑞医药盘中上涨3.01%，1类创新药鲁兹诺雷钠片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1118674931","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118674931?lang=zh_cn&edition=full","pubTime":"2026-05-29 11:57","pubTimestamp":1780027045,"startTime":"0","endTime":"0","summary":"5月29日，恒瑞医药盘中上涨3.01%，报59.95港元，成交额2.03亿港元。消息面上，公司5月28日公告，自主研发的1类创新药鲁兹诺雷钠片获国家药监局批准上市，该产品是中国首个自主研发的新一代高选择性URAT1抑制剂，适用于痛风伴高尿酸血症患者。中国高尿酸血症患者约1.8亿人，痛风患者约3600万人，目前全球在售同类药物仅有多替诺雷片一款，其全球销售额约3934万美元，竞争格局较优。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639142226","title":"恒瑞医药鲁兹诺雷钠片获批；赛诺医疗递交H股上市申请｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2639142226","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639142226?lang=zh_cn&edition=full","pubTime":"2026-05-29 07:00","pubTimestamp":1780009204,"startTime":"0","endTime":"0","summary":"｜2026年5月29日星期五｜NO.1石药集团+康宁杰瑞：安尼妥单抗注射液正式获批上市石药集团（HK01093）康宁杰瑞（HK09966）5月28日披露，双方联合研发的安尼妥单抗注射液获NMPA批准上市，适应证为联合化疗治疗既往经曲妥珠单抗治疗失败的HER2阳性晚期胃癌/胃食管结合部腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605293753219246.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293753219246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU2097828805.USD","LU1328615791.USD","BK1191","LU1580142542.USD","LU1969619763.USD","BK0251","LU2580892789.USD","LU1146622755.USD","LU2289578879.USD","IPOS","01276","159938","LU2495084118.USD","LU1781817850.SGD","LU1997244956.HKD","BK0183","BK0196","LU0405327494.USD","LU1064131003.USD","LU1997245177.USD","LU1997245094.SGD","LU0405327148.USD","LU2148510915.USD","09939","BK0060","LU2097828631.EUR","BK1515","LU0359201612.USD","BK0028","LU2328871848.SGD","BK0239","LU1820825898.SGD","LU2097828714.EUR","LU1655091616.SGD","600276","BK1574","LU0359202008.SGD","BK1161","LU2543165471.USD","BK0188","BK0012","LU1255011170.USD","688108","LU0359201885.HKD","LU2488822045.USD","LU1064130708.USD","LU2097828557.USD","LU1023057109.AUD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638699141","title":"恒瑞医药(01276)：SHR4640片获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2638699141","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638699141?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:51","pubTimestamp":1779976274,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司收到国家药品监督管理局的通知，批准公司自主研发的1类创新药鲁兹诺雷钠片上市，该产品是中国首个自主研发的新一代高选择性 URAT1 抑制剂。中国成人高尿酸血症患病率高达17.7%，约1.8亿人受其困扰;而痛风的患病率为3.2%，人数约 3600 万。全球范围内在售的痛风伴高尿酸血症的高选择性URAT1抑制剂仅有2020年1月获批的多替诺雷片，该产品已于2024年12月在中国获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","LU1997244956.HKD","LU1820825898.SGD","LU2488822045.USD","LU1969619763.USD","01276","BK0183","LU0359201612.USD","LU1064130708.USD","LU1997245177.USD","BK0028","LU1997245094.SGD","LU2148510915.USD","BK0196","LU2580892862.HKD","LU2097828805.USD","BK1191","BK0239","LU0359202008.SGD","BK0060","LU1781817850.SGD","LU2289578879.USD","LU2580892789.USD","BK0012","LU2097828631.EUR","LU0405327494.USD","LU1328615791.USD","600276","LU1023057109.AUD","LU1580142542.USD","LU1655091616.SGD","LU1255011170.USD","LU2328871848.SGD","LU2495084118.USD","LU2543165471.USD","LU2097828474.EUR","LU0405327148.USD","LU1146622755.USD","LU2097828557.USD","LU1064131003.USD","LU0359201885.HKD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667976","title":"恒瑞医药(600276.SH)：SHR-1819注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667976","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638667976?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:04","pubTimestamp":1779959083,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局核准签发关于SHR-1819注射液的《药物临床试验批准通知书》，将于近期开展临床试验。申请的适应症：6月-5岁儿童特应性皮炎。SHR-1819注射液是公司自主研发的一种靶向人IL-4Rα的重组人源化单克隆抗体，能够同时阻断IL-4和IL-13的信号传导，在研适应症覆盖特应性皮炎、结节性痒疹、慢性自发性荨麻疹、过敏性鼻炎等多种2型炎症疾病，多项已进入Ⅱ/Ⅲ期临床阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","LU2580892789.USD","LU1820825898.SGD","LU2488822045.USD","LU2580892862.HKD","LU2097828805.USD","BK0012","LU1146622755.USD","LU2543165471.USD","LU2097828474.EUR","600276","LU1064131003.USD","LU1023057109.AUD","LU2495084118.USD","01276","BK0188","LU1655091616.SGD","LU2328871848.SGD","BK0183","LU2289578879.USD","LU2097828557.USD","LU1328615791.USD","BK1191","LU1064130708.USD","BK0028","LU2148510915.USD","LU1781817850.SGD","LU1997245177.USD","LU0359201885.HKD","LU2097828631.EUR","LU0405327494.USD","LU0359201612.USD","LU0405327148.USD","LU1580142542.USD","LU1969619763.USD","BK0239","BK0060","LU2097828714.EUR","LU1997244956.HKD","LU1255011170.USD","LU1997245094.SGD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638570678","title":"智通AH统计|5月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638570678","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638570678?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:15","pubTimestamp":1779869706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月27日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为610.53%、403.21%、315.64%；宁德时代、兆易创新、药明康德分列AH溢价率末三位，溢价率分别为-29.02%、-26.90%、-3.96%。其中大唐发电、浙江世宝、东北电气的偏离值位居前三，分别为88.43%、48.29%、40.01%；另外，龙旗科技、胜宏科技、中国人寿的偏离值位居后三，分别为-20.27%、-15.89%、-12.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601318","00916","02338","02359","01108","01057","IE0032431581.USD","00991","00719","03678","IE0003895053.USD","02628","00568","82318","00042","02715","03143","01276","03200","01033","02476","02601","03750","02218","06031","LU0117844026.USD","03968","PNGAY","00300","HPAD.SI","01800","03347","EWH","LU2293587155.HKD","PAImain","03145","02727","02318","00553","02691","09611","LU0865486749.SGD","01812","03986","399300","01349","03296","00956","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638957196","title":"低位制药板块韧性凸显，华宝基金药ETF（562050）午后逆市拉升！权重股恒瑞医药冲高4%，中药龙头集体飘红","url":"https://stock-news.laohu8.com/highlight/detail?id=2638957196","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638957196?lang=zh_cn&edition=full","pubTime":"2026-05-27 14:22","pubTimestamp":1779862920,"startTime":"0","endTime":"0","summary":"5月27日午后，A股突发跳水，沪指失守4100点。制药板块局部异动，权重龙头恒瑞医药快速拉升翻红，一度冲高超4%；中药股逆市表现，云南白药、以岭药业、东阿阿胶、片仔癀等集体飘红。　　场内唯一表征制药板块整体行情的药ETF华宝午后自深水区直线拉升，截至发稿跌0.22%，沪指跌1.41%。　　低位布局“创新药+中药”，认准场内唯一药ETF华宝及其场外联接基金，汇聚A股50大龙头药企，在重仓创新药的同时，有约25%的权重为中药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-05-27/doc-inhzikrs0846612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2580892789.USD","LU1997244956.HKD","LU1997245094.SGD","BK0183","LU1023057109.AUD","LU2097828631.EUR","LU2495084118.USD","BK4588","BK0188","LU1997245177.USD","BK0012","LU1820825898.SGD","LU2543165471.USD","FDN","LU0359201885.HKD","LU1580142542.USD","LU0405327494.USD","BK1574","562050","BK4550","BK0060","LU0359202008.SGD","LU1781817850.SGD","LU2097828714.EUR","LU2328871848.SGD","LU2097828474.EUR","LU2289578879.USD","LU1064131003.USD","LU1146622755.USD","LU0405327148.USD","BK1191","LU2097828557.USD","LU2097828805.USD","LU1328615791.USD","01477","BK0196","BK0028","LU1969619763.USD","LU2148510915.USD","LU1064130708.USD","BK0239","LU1255011170.USD","LU0359201612.USD","LU2488822045.USD","LU1655091616.SGD","LU2580892862.HKD","01276","BK4585","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638592066","title":"恒瑞医药(600276.SH)：HRS-1635片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2638592066","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638592066?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:49","pubTimestamp":1779785384,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司成都盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-1635片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-1635片是公司自主研发的创新型抗肿瘤药物，拟用于治疗B细胞恶性肿瘤。经查询，目前国内外暂无同类药物获批上市。截至目前，HRS-1635片相关项目累计研发投入约2,360万元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892789.USD","LU1255011170.USD","LU1820825898.SGD","LU0359201885.HKD","LU0405327494.USD","BK1191","LU1997244956.HKD","LU1997245177.USD","LU2097828631.EUR","LU0359202008.SGD","01276","LU1146622755.USD","LU1064131003.USD","LU1023057109.AUD","BK0188","LU1969619763.USD","LU2580892862.HKD","LU2148510915.USD","LU1580142542.USD","LU1997245094.SGD","LU2488822045.USD","LU2097828474.EUR","BK0060","BK0183","LU2097828805.USD","LU1064130708.USD","BK0239","LU2495084118.USD","BK0028","LU0405327148.USD","LU0359201612.USD","LU2328871848.SGD","LU2289578879.USD","BK0196","600276","LU2097828557.USD","LU2097828714.EUR","LU1781817850.SGD","LU1655091616.SGD","BK0012","LU1328615791.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638558983","title":"恒瑞医药：公司2025年度利润分配方案经公司2025年年度股东会审议通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2638558983","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638558983?lang=zh_cn&edition=full","pubTime":"2026-05-25 20:21","pubTimestamp":1779711660,"startTime":"0","endTime":"0","summary":"证券日报网讯5月25日，恒瑞医药在互动平台回答投资者提问时表示，公司2025年度利润分配方案经公司2025年年度股东会审议通过，将按既定方案进行，具体详见公司在交易所网站发布的公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253748385364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU2097828805.USD","LU1328615791.USD","BK1191","LU1580142542.USD","LU1969619763.USD","LU1064130708.USD","LU2580892789.USD","LU2289578879.USD","01276","LU2495084118.USD","LU1781817850.SGD","LU1997244956.HKD","BK0183","BK0196","LU0405327494.USD","LU1064131003.USD","LU1997245177.USD","LU1997245094.SGD","LU0405327148.USD","LU2148510915.USD","BK0060","LU2097828631.EUR","LU0359201612.USD","BK0028","LU2328871848.SGD","BK0239","LU1820825898.SGD","LU2097828714.EUR","LU1655091616.SGD","600276","LU0359202008.SGD","LU2543165471.USD","BK0188","BK0012","LU1255011170.USD","LU0359201885.HKD","LU2488822045.USD","LU1146622755.USD","LU2097828557.USD","LU1023057109.AUD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638535260","title":"智通AH统计|5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638535260","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638535260?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:15","pubTimestamp":1779696907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月25日收盘，东北电气、浙江世宝、安德利果汁分列AH溢价率前三位，溢价率分别为610.53%、402.67%、321.80%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-29.65%、-20.62%、-4.35%。其中大唐发电、安德利果汁、浙江世宝的偏离值位居前三，分别为82.87%、66.90%、53.24%；另外，上海电气、龙旗科技、京城机电股份的偏离值位居后三，分别为-33.54%、-17.88%、-17.86%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03143","00981","02628","03145","03750","00719","06613","01276","LU1115378108.SGD","PNGAY","02899","00187","00916","06127","80883","00956","03986","HPAD.SI","02601","00895","09611","06031","01057","01800","601318","03296","00300","00991","02359","00883","01349","02338","82318","03968","LU0651947912.USD","00553","03678","EWH","01171","01812","01108","159982","399300","PAImain","02218","02318","00042","01033","02727"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637126963","title":"恒瑞医药：2025年公司创新药销售收入163.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637126963","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637126963?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:59","pubTimestamp":1779454740,"startTime":"0","endTime":"0","summary":"证券日报网讯5月22日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持科技创新战略，已在中国获批上市24款1类创新药、5款2类新药，另有100多个自主创新产品正在临床开发，400余项临床试验在国内外开展。经营业绩方面，创新成果转化高效赋能，创新药销售引领业绩增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223747010910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU2543165471.USD","LU1997245177.USD","BK0012","LU1997244956.HKD","LU1023057109.AUD","01276","BK1161","LU1781817850.SGD","BK1191","LU1969619763.USD","LU2580892789.USD","LU1255011170.USD","BK0188","LU1655091616.SGD","06978","LU1064131003.USD","LU1580142542.USD","LU2097828714.EUR","LU2495084118.USD","BK0183","LU1820825898.SGD","BK1574","BK0196","LU2097828631.EUR","LU0359202008.SGD","159992","LU1997245094.SGD","LU2097828474.EUR","LU1146622755.USD","LU2097828557.USD","LU0405327494.USD","LU0359201885.HKD","LU2097828805.USD","LU1064130708.USD","LU2328871848.SGD","600276","LU0405327148.USD","LU0359201612.USD","LU2488822045.USD","LU1328615791.USD","LU2580892862.HKD","LU2289578879.USD","LU2148510915.USD","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637391065","title":"智通AH统计|5月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=2637391065","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637391065?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:15","pubTimestamp":1779437706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月22日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为610.53%、386.64%、304.56%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-28.21%、-27.83%、-4.15%。其中大唐发电、东北电气、浙江世宝的偏离值位居前三，分别为86.78%、45.81%、39.50%；另外，上海电气、龙旗科技、东江环保的偏离值位居后三，分别为-34.55%、-20.97%、-16.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06031","02691","02359","03968","PAImain","00501","06127","02218","03143","159982","HPAD.SI","01812","03750","09611","02476","02628","PNGAY","399300","80883","01800","00981","00187","03296","03678","01171","01349","IE0008369823.USD","00991","03145","00956","01033","601318","00916","02338","00883","03986","00895","01276","06613","02899","01108","02727","02318","00553","82318","EWH","01057","00042","00300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191905171","title":"异动解读｜恒瑞医药盘中上涨3.44%，BMS合作后连续回调企稳反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1191905171","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191905171?lang=zh_cn&edition=full","pubTime":"2026-05-21 13:09","pubTimestamp":1779340193,"startTime":"0","endTime":"0","summary":"5月21日，恒瑞医药盘中上涨3.44%，报63.15港元，成交额1.06亿港元。此前公司与百时美施贵宝达成潜在总额约152亿美元的全球战略合作协议，消息公布当日港股一度涨超16%，但随后连续多个交易日回调累计跌幅超10%。当日制药板块整体走强，行业个股中凯莱英涨10.28%、中国生物制药涨2.51%，板块联动亦提振市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636845172","title":"恒瑞医药：每股派0.2元，股权登记日为5月26日","url":"https://stock-news.laohu8.com/highlight/detail?id=2636845172","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636845172?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:21","pubTimestamp":1779272460,"startTime":"0","endTime":"0","summary":"南财智讯5月20日电，恒瑞医药发布2025年年度权益分派实施公告，公司本次利润分配方案为每股派发现金红利0.2元（含税），共计派发现金红利12.74亿元。本次权益分派股权登记日为2026年5月26日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743627742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1820825898.SGD","BK0060","LU2097828805.USD","LU2097828714.EUR","01276","LU1997245177.USD","LU1023057109.AUD","LU1146622755.USD","BK0188","LU2097828631.EUR","LU2580892862.HKD","600276","LU2097828557.USD","LU2289578879.USD","LU2097828474.EUR","LU2488822045.USD","BK1191","LU0359201885.HKD","LU0405327148.USD","BK0012","BK0239","LU1255011170.USD","LU1969619763.USD","LU2148510915.USD","LU2543165471.USD","LU1997245094.SGD","LU1781817850.SGD","LU2328871848.SGD","LU1997244956.HKD","LU1580142542.USD","BK0196","BK0028","LU0359201612.USD","LU1064130708.USD","LU1064131003.USD","LU1655091616.SGD","LU1328615791.USD","LU2495084118.USD","LU2580892789.USD","BK0183","LU0359202008.SGD","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636814105","title":"智通AH统计|5月20日","url":"https://stock-news.laohu8.com/highlight/detail?id=2636814105","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636814105?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:15","pubTimestamp":1779264907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月20日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为583.54%、378.80%、325.76%；宁德时代、兆易创新、药明康德分列AH溢价率末三位，溢价率分别为-25.01%、-24.34%、-4.49%。其中安德利果汁、南华期货股份、新天绿色能源的偏离值位居前三，分别为59.87%、39.10%、37.43%；另外，上海电气、龙旗科技、中国交通建设的偏离值位居后三，分别为-36.77%、-22.21%、-16.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00553","03145","01339","02880","02218","01812","03678","01108","06031","HPAD.SI","02727","LU1960683339.HKD","00187","00956","LU1242518857.USD","01033","02359","IE00BPRC5H50.USD","03750","PAImain","03968","06127","02628","EWH","00638","01288","01800","01276","01057","06613","02338","03986","159982","00895","00568","02476","03296","03143","PNGAY","01349","00300","82318","09611","02691","03328","02318","00042","601318","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636896784","title":"深耕肠外营养领域，恒瑞医药新产品获批强化管线矩阵｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2636896784","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636896784?lang=zh_cn&edition=full","pubTime":"2026-05-20 09:22","pubTimestamp":1779240142,"startTime":"0","endTime":"0","summary":"截至5月19日收盘，市场探底回升，沪指、深成指先后翻红。医药ETF（512120）收平，港股通生物科技ETF（159102）上涨0.27%。相关个股中，恒瑞医药下跌1.6%、药明合联上涨3.28%、科伦博泰生物上涨1.27%、万泰生物下跌1.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203742884813.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203742884813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2289578879.USD","BK0239","LU0359201612.USD","LU2097828474.EUR","LU1146622755.USD","LU2097828631.EUR","BK0196","LU2097828714.EUR","LU1255011170.USD","LU1023057109.AUD","LU0359201885.HKD","LU1997244956.HKD","LU2495084118.USD","LU0405327148.USD","BK0012","LU0405327494.USD","LU1328615791.USD","600276","BK1191","LU1997245094.SGD","LU2097828557.USD","BK1515","BK0183","LU1655091616.SGD","09939","LU2543165471.USD","LU1064130708.USD","BK1161","LU1969619763.USD","LU0359202008.SGD","LU1820825898.SGD","01276","BK0028","LU1997245177.USD","BK0188","BK0060","LU2097828805.USD","LU2148510915.USD","159938","LU2328871848.SGD","LU2580892789.USD","BK1574","LU1580142542.USD","LU2580892862.HKD","LU1781817850.SGD","LU1064131003.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0187},{"period":"1month","weight":-0.0954},{"period":"3month","weight":-0.0916},{"period":"6month","weight":-0.1814},{"period":"1year","weight":0.0506},{"period":"ytd","weight":-0.1521}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0544},{"period":"6month","weight":-0.0262},{"period":"1year","weight":0.0683},{"period":"ytd","weight":-0.0175}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}